Invivyd, Inc. insider trading
Every open-market purchase and sale by Invivyd, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $125,000 1 trade by 1 insider
3 months later: median −34.0% (−37.9% vs S&P 500) Insider sales, 5 years $531,074 20 trades by 5 insiders
3 months later: median −33.4% (−41.4% vs S&P 500)
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Invivyd, Inc.’s insiders pay?
From August 19, 2022 to November 20, 2025, 5 insiders reported 3 open-market purchases and 7 sales not made under a pre-set plan in Invivyd, Inc.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Mcguire Terrance | Director | 0 | — | — | 6 | — | December 31, 2024 |
| Adimab, LLC | 10% owner | 0 | — | — | 1 | — | January 22, 2024 |
| Elia Marc | Director | 1 | — | — | 0 | — | August 19, 2022 |
| Hering David | Chief Executive Officer | 1 | — | — | 0 | — | September 1, 2022 |
| Mclaughlin Kevin F | Director | 1 | — | — | 0 | — | November 20, 2025 |